According to a study published in the journal Annals of Internal Medicine, a meta-analysis of COVID-19 experiments revealed that a unique combination of symptoms and viral rebound following untreated COVID-19 infection occurs in only 3% of study participants.

The researchers stated that the reports of deteriorating symptoms and virologic rebound following the conclusion of treatment have been associated with the widespread use of nirmatrelvir, a medication that is advised for outpatients with mild to moderate COVID-19.

In the study, researchers from Brigham and Women′s Hospital, US, analyzed the data collected from 563 participants who received a placebo in the current trial. The findings of the study showed that 11 days after the first onset of symptoms, 26% of participants experienced symptom rebound only, whereas 31% of individuals experienced virus rebound only. Meanwhile, a high viral rebound was seen in 13% of participants.

Furthermore, the research team discovered that the majority of patients experienced symptoms and virus rebound that lasted no more than one day. Furthermore, the authors pointed out that the findings of the study underscore the importance of taking into consideration the rates of symptom recurrence in the absence of antiviral therapy when assessing the efficacy of antiviral treatments. 

(Source: https://www.tribuneindia.com/news/health/symptom-and-viral-rebound-rare-after-untreated-covid-19-infection-study-481854 )